Alexander Graham Heriot

Alexander Graham Heriot

Auto-generated profile, based on publicly available information

Alexander Graham Heriot

Division of Cancer Surgery, Division of Cancer Research Peter MacCallum Cancer Centre Melbourne Victoria Australia

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2008 in Diseases of the Colon & Rectum
Verified
Journal Article
Closed access
AHAlexander G. Heriot
Alexander G. Heriot
CBChristopher M. Byrne
Christopher M. Byrne
PLPeter Lee
Peter Lee
BDBruce Dobbs
Bruce Dobbs
HTHenry Tilney
Henry Tilney
FFFrank Frizelle
Frank Frizelle
Surgery for recurrent rectal cancer is the only therapy with curative potential. This study was designed to assess factors that affect survival after surgery for locally recurrent rectal cancer. Prospective databases of patients undergoing surgical resection for recurrent rectal cancer at three tertiary centers between 1990 and 2006 were combined and analyzed. Cox regression and Kaplan-Meier survival analysis were used to assess factors associated with survival. A total of 160 patients (96 males) underwent surgery (median age, 63 (range, 27-93) years). Ninety-five patients (59 percent) received neoadjuvant radiotherapy. Sixty-three patients (39 percent) underwent radical resection and 90 (56 percent) underwent extended radical resection. Seven patients (5 percent) were irresectable. There was one death and 27 percent had major postoperative complications, independent of extent of resection. Negative resection margins were obtained in 98 patients (R0 61 percent). Median cancer-specific and overall survival was 48 months (41.5 percent 5-year survival) and 43 months (36.6 percent 5-year survival), respectively. Margin involvement was a significant predictor of cancer-specific (P<0.001) and overall survival (P<0.02). Resection for recurrent rectal cancer results in good survival with acceptable morbidity, unaffected by the extent of resection. Extended radical resection to obtain clear resection margins is the appropriate management of locally recurrent rectal cancer.

15 July 2020 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
VNVignesh Narasimhan
Vignesh Narasimhan
JWJosephine A. Wright
Josephine A. Wright
MCMichael Churchill
Michael Churchill
TWTongtong Wang
Tongtong Wang
RRRachele Rosati
Rachele Rosati
SWSusan L. Woods
Susan L. Woods
Purpose: Patients with colorectal cancer with peritoneal metastases (CRPMs) have limited treatment options and the lowest colorectal cancer survival rates. We aimed to determine whether organoid testing could help guide precision treatment for patients with CRPMs, as the clinical utility of prospective, functional drug screening including nonstandard agents is unknown. Experimental Design: CRPM organoids (peritonoids) isolated from patients underwent parallel next-generation sequencing and medium-throughput drug panel testing ex vivo to identify specific drug sensitivities for each patient. We measured the utility of such a service including: success of peritonoid generation, time to cultivate peritonoids, reproducibility of the medium-throughput drug testing, and documented changes to clinical therapy as a result of the testing. Results: Peritonoids were successfully generated and validated from 68% (19/28) of patients undergoing standard care. Genomic and drug profiling was completed within 8 weeks and a formal report ranking drug sensitivities was provided to the medical oncology team upon failure of standard care treatment. This resulted in a treatment change for two patients, one of whom had a partial response despite previously progressing on multiple rounds of standard care chemotherapy. The barrier to implementing this technology in Australia is the need for drug access and funding for off-label indications. Conclusions: Our approach is feasible, reproducible, and can guide novel therapeutic choices in this poor prognosis cohort, where new treatment options are urgently needed. This platform is relevant to many solid organ malignancies.

3 March 2009 in British Journal of Cancer
Verified
Journal Article
Open access
EWE de Winton
E de Winton
AHA G Heriot
A G Heriot
MNM Ng
M Ng
RHR J Hicks
R J Hicks
AHA Hogg
A Hogg
SNS Y Ngan
S Y Ngan
Accurate inguinal and pelvic nodal staging in anal cancer is important for the prognosis and planning of radiation fields. There is evidence for the role of 18-fluorodeoxyglucose positron emission tomography (FDG-PET) in the staging and management of cancer, with early reports of an increasing role in outcome prognostication in a number of tumours. We aimed to determine the effect of FDG-PET on the nodal staging, radiotherapy planning and prognostication of patients with primary anal cancer. Sixty-one consecutive patients with anal cancer who were referred to a tertiary centre between August 1997 and November 2005 were staged with conventional imaging (CIm) (including computed tomography (CT), magnetic resonance imaging, endoscopic ultrasound and chest X-ray) and by FDG-PET. The stage determined by CIm and the proposed management plan were prospectively recorded and changes in stage and management as a result of FDG-PET assessed. Patients were treated with a uniform radiotherapy technique and dose. The accuracy of changes and prognostication of FDG-PET were validated by subsequent clinical follow-up. Kaplan–Meier survival analysis was used to estimate survival for the whole cohort and by FDG-PET and CIm stage. The tumour-stage group was changed in 23% (14 out of 61) as a result of FDG-PET (15% up-staged, 8% down-staged). Fourteen percent of T1 patients (3 out of 22), 42% of T2 patients (10 out of 24) and 40% of T3–4 patients (6 out of 15) assessed using CIm, had a change in their nodal or metastatic stage following FDG-PET. Sensitivity for nodal regional disease by FDG-PET and CIm was 89% and 62%, respectively. The staging FDG-PET scan altered management intent in 3% (2 out of 61) and radiotherapy fields in 13% (8 out of 61). The estimated 5-year overall survival (OS) and progression-free survival (PFS) for the cohort were 77.3% (95% confidence interval (CI): 55.3–90.4%) and 72.2% (95% CI: 51.5–86.4%), respectively. The estimated 5-year PFS for FDG-PET and CIm staged N2-3 disease was 70% (95% CI: 42.8–87.9%) and 55.3% (95% CI: 23.3–83.4%), respectively. FDG-PET shows increased sensitivity over CIm for staging nodal disease in anal cancer and changes treatment intent or radiotherapy prescription in a significant proportion of patients.

28 July 2021 in Colorectal Disease
Verified
Journal Article
Closed access
PDF file
JFJulie Flynn
Julie Flynn
JLJosé Tomás Larach
José Tomás Larach
JKJoseph C. H. Kong
Joseph C. H. Kong
PWPeadar S. Waters
Peadar S. Waters
SWSatish K. Warrier
Satish K. Warrier
AHAlexander Heriot
Alexander Heriot

24 August 2006 in Colorectal Disease
Verified
Journal Article
Closed access
PDF file
AHA. G. Heriot
A. G. Heriot
PTP. P. Tekkis
P. P. Tekkis
ADA. Darzi
A. Darzi
JMJ. Mackay
J. Mackay

20 February 2021 in International Journal of Colorectal Disease
Verified
Journal Article
Closed access
PDF file
JFJulie Flynn
Julie Flynn
JLJose T. Larach
Jose T. Larach
JKJoseph C. H. Kong
Joseph C. H. Kong
SWSatish K. Warrier
Satish K. Warrier
AHAlexander Heriot
Alexander Heriot